Improving hypertension care in Ghana and Baltimore

Addressing Hypertension Care in Africa (ADHINCRA) Program

Not applicable Interventional Johns Hopkins University · NCT06986590

This program tests whether a package of patient-, provider-, and health-system interventions can improve blood pressure control for adults ages 18–70 with hypertension who receive care at participating clinics and own a smartphone.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment800 (estimated)
Ages18 Years to 70 Years
SexAll
SponsorJohns Hopkins University Academic / other
Locations17 sites (Baltimore, Maryland and 16 other locations)
Trial IDNCT06986590 on ClinicalTrials.gov

What this trial studies

The ADHINCRA Program implements a bundle of multilevel, evidence-based interventions that address patient-, provider-, and health-system factors contributing to uncontrolled hypertension. The program is being delivered at primary care sites in the Ashanti Region of Ghana and at Johns Hopkins in Baltimore, with smartphone-supported components and clinic-based workflow changes. Eligible participants are adults 18–70 with systolic BP ≥140 mmHg who are treatment-naive or on monotherapy, while people with severe hypertension, diabetes, established cardiovascular or kidney disease, pregnancy, or cognitive impairment are excluded. The aim is to increase hypertension control rates and produce a rigorous, scalable model for wider adoption to reduce future cardiovascular, stroke, and kidney disease risk.

Who should consider this trial

Good fit: Adults aged 18–70 with diagnosed hypertension (systolic BP ≥140 mmHg) who are treatment-naive or on a single antihypertensive, receive primary care at a participating site, can consent in a study language, and own a smartphone are ideal candidates.

Not a fit: Patients with severely elevated BP (≥180/110 mmHg), diabetes, prior stroke or coronary or kidney disease, end-stage renal disease on dialysis, pregnancy, cognitive impairment, or those without a smartphone are unlikely to qualify or benefit from this program.

Why it matters

Potential benefit: If successful, the program could improve blood pressure control and lower the risk of heart attack, stroke, and kidney disease by providing a scalable care model.

How similar studies have performed: Similar multilevel and digital-support interventions in low- and middle-income settings have improved blood pressure control in other programs, although effectiveness and scalability have varied by context.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Aged 18 -70 years.
* Diagnosis of hypertension and elevated systolic blood pressure measure (≥140 mmHg) on the most recent clinic visit without a diabetes diagnosis.
* Hypertension treatment naive or on monotherapy.
* Receives primary care at one of the participating sites.
* Willing and able to provide informed consent in English, Twi, Dagbani, Ewe, Hausa, or Yoruba.
* Owns a smartphone (Android or iOS).

Exclusion Criteria:

* Age \<18 years or \>70 years.
* Severely elevated BP (≥180/110mmHg).
* Diagnosis of stroke, coronary artery disease, or kidney disease.
* Diagnosis of end-stage renal disease (ESRD) treated with dialysis.
* Serious medical condition which either limits life expectancy or requires active management (e.g., cancer).
* Cognitive impairment or other conditions preventing study participation
* Pregnant or currently nursing a child
* Unwilling to provide informed consent

Where this trial is running

Baltimore, Maryland and 16 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions HypertensionHigh Blood Pressure
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.